PMV Pharmaceuticals, Inc.
PMVP
$1.26
$0.032.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.58% | 12.67% | 13.69% | 11.02% | -15.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.25% | 19.89% | 16.41% | 5.88% | -4.63% |
| Operating Income | -17.25% | -19.89% | -16.41% | -5.88% | 4.63% |
| Income Before Tax | -25.66% | -27.57% | -21.62% | -8.48% | 6.86% |
| Income Tax Expenses | 86.35% | 86.90% | -609,966.67% | -536,733.33% | -402,600.00% |
| Earnings from Continuing Operations | -60.70% | -65.45% | 6.49% | 14.87% | 29.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.70% | -65.45% | 6.49% | 14.87% | 29.06% |
| EBIT | -17.25% | -19.89% | -16.41% | -5.88% | 4.63% |
| EBITDA | -19.29% | -21.57% | -17.57% | -6.12% | 5.28% |
| EPS Basic | -58.50% | -61.45% | 11.14% | 21.28% | 35.95% |
| Normalized Basic EPS | -25.07% | -26.18% | -16.74% | 0.42% | 16.66% |
| EPS Diluted | -58.50% | -61.45% | 11.14% | 21.28% | 35.95% |
| Normalized Diluted EPS | -25.07% | -26.18% | -16.74% | 0.42% | 16.66% |
| Average Basic Shares Outstanding | 1.40% | 1.96% | 4.62% | 7.44% | 10.49% |
| Average Diluted Shares Outstanding | 1.40% | 1.96% | 4.62% | 7.44% | 10.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |